Merck KGaA Sells Off Cancer Med Rights to PDS Biotech for Over $120 Million

German pharma powerhouse Merck KGaA is continuing its R&D deal hot streak, signaling an increased ambition to offload commercially promising assets. The company is ringing in the new year with an over $120 million transaction that will grant the rights to its IL-12-targeting cancer drug, M9241...